GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » E10

Sunshine Biopharma (Sunshine Biopharma) E10 : $-44,288.80 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sunshine Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was $-200.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-44,288.80 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 22.30% per year. During the past 5 years, the average E10 Growth Rate was 24.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sunshine Biopharma was 24.40% per year. The lowest was 21.60% per year. And the median was 22.10% per year.

As of today (2024-06-07), Sunshine Biopharma's current stock price is $0.5579. Sunshine Biopharma's E10 for the quarter that ended in Mar. 2024 was $-44,288.80. Sunshine Biopharma's Shiller PE Ratio of today is .


Sunshine Biopharma E10 Historical Data

The historical data trend for Sunshine Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma E10 Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -198,430.00 -112,996.00 -103,776.00 -95,510.60 -52,936.20

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -70,294.60 -68,362.00 -65,657.80 -52,936.20 -44,288.80

Competitive Comparison of Sunshine Biopharma's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Shiller PE Ratio falls into.



Sunshine Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sunshine Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-200/126.2576*126.2576
=-200.000

Current CPI (Mar. 2024) = 126.2576.

Sunshine Biopharma Quarterly Data

per share eps CPI Adj_EPS
201406 -95,689.100 99.473 -121,454.462
201409 -35,106.100 99.394 -44,594.227
201412 -37,079.700 98.367 -47,593.087
201503 -24,530.600 99.789 -31,037.142
201506 -34,500.800 100.500 -43,342.994
201509 -12,675.900 100.421 -15,937.128
201512 -26,986.600 99.947 -34,090.599
201603 -10,527.400 101.054 -13,153.075
201606 -14,156.200 102.002 -17,522.547
201609 -20,071.100 101.765 -24,901.871
201612 -11,713.200 101.449 -14,577.648
201703 -1,918.650 102.634 -2,360.279
201706 -4,494.850 103.029 -5,508.261
201709 -1,294.830 103.345 -1,581.911
201712 -1,855.080 103.345 -2,266.376
201803 -2,251.150 105.004 -2,706.800
201806 -4,668.900 105.557 -5,584.510
201809 -4,583.620 105.636 -5,478.406
201812 -1,582.500 105.399 -1,895.679
201903 -908.260 106.979 -1,071.935
201906 -2,734.190 107.690 -3,205.602
201909 -450.181 107.611 -528.186
201912 -224.713 107.769 -263.264
202003 -50.164 107.927 -58.684
202006 -200.000 108.401 -232.945
202009 -49.747 108.164 -58.068
202012 -62.575 108.559 -72.776
202103 -282.000 110.298 -322.805
202106 -121.000 111.720 -136.745
202109 -159.000 112.905 -177.804
202112 25.745 113.774 28.570
202203 -23.446 117.646 -25.162
202206 -3.000 120.806 -3.135
202209 -8.000 120.648 -8.372
202212 -150.000 120.964 -156.564
202303 -773.000 122.702 -795.399
202306 -2.000 124.203 -2.033
202309 -4.000 125.230 -4.033
202312 -5.700 125.072 -5.754
202403 -200.000 126.258 -200.000

Add all the adjusted EPS together and divide 10 will get our e10.


Sunshine Biopharma  (NAS:SBFM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sunshine Biopharma E10 Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3

Sunshine Biopharma (Sunshine Biopharma) Headlines

From GuruFocus

Sunshine Biopharma: An Opportunity Knocking?

By Ishan Majumdar 05-09-2022

Sunshine Biopharma Initiates COVID-19 Treatment Mice Study

By ACCESSWIRE ACCESSWIRE 02-10-2021